Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership cut its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 86.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,453 shares of the company’s stock after selling 139,190 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in Kiniksa Pharmaceuticals were worth $444,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. grew its stake in Kiniksa Pharmaceuticals by 138.9% in the 4th quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company’s stock worth $9,451,000 after acquiring an additional 277,827 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth $158,000. Teacher Retirement System of Texas grew its position in shares of Kiniksa Pharmaceuticals by 7.1% in the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock valued at $215,000 after purchasing an additional 719 shares during the period. Globeflex Capital L P increased its stake in Kiniksa Pharmaceuticals by 217.1% in the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company’s stock valued at $1,752,000 after purchasing an additional 60,656 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Kiniksa Pharmaceuticals during the fourth quarter worth about $3,955,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Insider Buying and Selling

In related news, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total transaction of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares of the company’s stock, valued at approximately $1,604,250.75. The trade was a 14.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Mark Ragosa sold 36,372 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total value of $809,277.00. Following the completion of the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at approximately $510,815.50. This represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 79,766 shares of company stock valued at $1,756,375. Company insiders own 54.57% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the company. Wedbush restated an “outperform” rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They issued a “buy” rating and a $40.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $37.17.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $19.31 on Monday. Kiniksa Pharmaceuticals, Ltd. has a 12 month low of $16.56 and a 12 month high of $28.15. The company has a market cap of $1.40 billion, a price-to-earnings ratio of -137.92 and a beta of 0.31. The stock’s 50-day moving average is $20.97 and its 200-day moving average is $21.60.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same period last year, the firm earned $0.35 earnings per share. The company’s quarterly revenue was up 46.9% on a year-over-year basis. Research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.